# A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

Study · id `cardio:ct-nct05514535` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05514535](<https://clinicaltrials.gov/study/NCT05514535>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05514535

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 573 participants.

## Technical summary

Registry record NCT05514535. Randomized; no masking; primary purpose treatment. Start 2022-08-29 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-05-11.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 573 participants (enrolled count; ClinicalTrials.gov record NCT05514535, source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)
- Started: 2022-08-29 (actual) (ClinicalTrials.gov record NCT05514535, source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)
- Primary completion: 2025-03-05 (actual) (ClinicalTrials.gov record NCT05514535, source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)
- Completion: 2025-04-09 (actual) (ClinicalTrials.gov record NCT05514535, source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)
- Results first posted: 2026-05-11 (ClinicalTrials.gov record NCT05514535, source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)
- Countries: United States; Czechia; Greece; Italy; Portugal; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Ukraine (ClinicalTrials.gov record NCT05514535, source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05514535-2026-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- Condition: Diabetes Mellitus, Type 2
- Condition: Obesity
- Intervention (Drug): Semaglutide
- Intervention (Drug): Insuline glargine U100 (reduced)
- Intervention (Drug): Insuline glargine U100 (titrated)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 7f4dea1c0bd63c0f23e54f3822aa78c27d73285ca46b9383bd79174e1a91898d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
